Prevention

Why?

• It reduces death and hospitalisation compared with placebo. ^a

ACE inhibitors reduce death and hospitalisation

Patient	Treatment	Comparison	Outcome	CER	OR (95% CI)	NNT (95% CI)
severe heart failure a	ACE inhibitor	placebo	death at 3 months	22%	0.77 (0.67 to 0.88)	24 (16 to 47)
			death or hospitalisation at 3 months	33%	0.65 (0.57 to 0.74)	12 (9 to 16)

• It reduces death compared with isosorbide-mononitrate and hydralazine ^a and is more cost-effective. ^a

Enalapril reduces death and treatment withdrawal better than isosorbide-mononitrate and hydralazine

Patient	Treatment	Comparison	Outcome	CER	RRR (95% CI)	NNT (95% CI)
men with chronic heart failure a	enalapril	isosorbide-dinitrate and hydralazine	death at 2 years	25%	28% (6% to 45%)	14 (8 to 70)
			medication stopped at 5 years	29%	24% (3% to 40%)	15 (8 to 120)